Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

Share Price is delayed by 15 minutes
Get Live Data
50.00    0.00 (0.00%)
Bid:
49.00
Ask:
51.00
Spread: 2.00 (4.082%)
Market Cap: £83.71m
MAV4 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g 4 Share Chart

Statement re Offer for Subscription

10 Jan 2022 12:43

RNS Number : 9606X
Maven Income and Growth VCT 3 PLC
10 January 2022
 

Maven Income and Growth VCT 3 PLC and Maven Income and Growth VCT 4 PLC (the Companies)

 

Offers for Subscription - Early Investment Incentive

 

10 January 2022

 

On 20 September 2021, the Companies published a joint Prospectus (comprising a Securities Note, Registration Document and Summary) in relation to offers for subscription of new Ordinary Shares of 10p each (together the "Offers" and each an "Offer").

 

In the Prospectus, it was stated that all valid applications that were received (together with their relevant application monies) by the deadline of 12.00 noon on 28 January 2022 would be eligible to receive an Early Investment Incentive discount under the Offers. Existing Shareholders (and their spouses or partners) in any of the Maven VCTs, including the Companies, at the time the application was received would benefit from an enhanced rate of discount in recognition of their continued support for the Maven VCTs. The levels of discount to be applied would be:

 

· 1.5% of the application amount for Existing Shareholders; and

· 1.25% of the application amount for New Investors.

 

It was also stated that each Company could, in consultation with Maven Capital Partners UK LLP (Maven) and in their absolute discretion, extend the deadline by which applications must be received to be eligible for the Early Investment Incentive under its Offer.

 

The Board of each Company confirms that the deadline by which applications must be received to be eligible for the Early Investment Incentive under their Company's respective Offer has been extended until close of business on Wednesday 2 February 2022. Furthermore, it is anticipated that both Companies will make initial allotments of new Ordinary Shares under their respective Offers as soon as practicable after that date.

 

Further information

 

Any enquiries in respect of the Offers, or requests for copies of the Prospectus documents (available free of charge), should be directed to:

 

Maven Capital Partners UK LLP

Kintyre House

205 West George Street

Glasgow

G2 2LW

 

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

 

Downloadable versions of the Prospectus documents are available from the Maven website at: www.mavencp.com/vctoffer.

Maven Capital Partners UK LLPSecretary

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRFLFSFLIIILIF
Date   Source Headline
2nd Oct 202012:41 pmRNSIssue of Equity
29th Sep 20204:49 pmRNSStatement re Dividend Investment Scheme
1st Sep 20204:35 pmRNSTransaction in Own Shares
28th Aug 20202:38 pmRNSHalf-year Report
26th Aug 20205:26 pmRNSTransaction in Own Shares
20th Aug 202011:38 amRNSStatement re NAV, Interim Dividend and DIS
20th Aug 202011:29 amRNSDirector Declaration
9th Jul 202010:00 amRNSIssue of Equity
8th Jun 20209:36 amRNSAllotment Update
21st May 202012:17 pmRNSResult of AGM
15th May 20204:10 pmRNSNet Asset Value(s)
7th May 20204:35 pmRNSPublication of Suppl.Prospcts
21st Apr 20206:24 pmRNSAnnual Financial Report
8th Apr 20203:56 pmRNSStatement re Offer for Subscription
26th Mar 20205:25 pmRNSUpdate on Net Asset Value
26th Mar 20205:00 pmRNSAllotment Update and Suspension of DIS
20th Mar 20204:57 pmRNSTransaction in Own Shares
28th Feb 20204:56 pmRNSTransaction in Own Shares
24th Feb 20204:35 pmRNSStatement re Net Asset Value and Proposed Dividend
11th Feb 20205:04 pmRNSDirector/PDMR Shareholding
11th Feb 20205:02 pmRNSDirector/PDMR Shareholding
11th Feb 20204:24 pmRNSIssue of Equity
6th Feb 20203:39 pmRNSStatement re Offer for Subscription
18th Dec 20192:14 pmRNSDirectorate Change
18th Dec 20192:09 pmRNSMerger Update: Approval of Scheme
10th Dec 201912:30 pmRNSResult of General Meeting
14th Nov 20196:20 pmRNSStatement re Offer for Subscription
14th Nov 20196:20 pmRNSStatement re Proposed Merger
7th Nov 20192:11 pmRNSNet Asset Value(s)
4th Oct 201911:30 amRNSDirector/PDMR Shareholding
4th Oct 201910:22 amRNSIssue of Equity
1st Oct 201912:34 pmRNSNet Asset Value(s)
20th Sep 201912:44 pmRNSHalf-year Report
19th Sep 20193:46 pmRNSTransaction in Own Shares
17th Sep 20193:00 pmRNSTransaction in Own Shares
28th Aug 20192:59 pmRNSStatement re Possible Merger
27th Aug 20194:38 pmRNSStatement re NAV and Interim Dividend
23rd Aug 20194:23 pmRNSStatement re Intended Joint Offer for Subscription
21st Aug 20194:14 pmRNSStatement re share premium account cancellation
21st May 20194:04 pmRNSTransaction in Own Shares
15th May 20195:02 pmRNSNet Asset Value(s)
15th May 20192:08 pmRNSResult of AGM
5th Apr 20193:25 pmRNSAnnual Financial Report
12th Mar 20192:52 pmRNSTransaction in Own Shares
28th Feb 20194:03 pmRNSNet Asset Value(s)
4th Dec 20184:42 pmRNSTransaction in Own Shares
27th Nov 20183:15 pmRNSTransaction in Own Shares
22nd Nov 20183:14 pmRNSTransaction in Own Shares
19th Nov 201811:45 amRNSDirector/PDMR Shareholding
19th Nov 201811:43 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.